ES2670029T3 - Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D - Google Patents

Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D Download PDF

Info

Publication number: ES2670029T3
Authority: ES; Spain
Prior art keywords: vitamin; patient; compound; hydroxyvitamin; levels
Prior art date: 2006-06-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES13177274.1T

Other languages

English (en)

Spanish (es)

Inventor

Charles W. Bishop

Keith H. Crawford

Eric J. Messner

P. Martin Petkovich

Christian F. Helvig

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Opko Ireland Global Holdings Ltd

Opko Renal LLC

Original Assignee

Opko Ireland Global Holdings Ltd

Opko Renal LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-21

Filing date

2007-06-21

Publication date

2018-05-29

2007-06-21 Application filed by Opko Ireland Global Holdings Ltd, Opko Renal LLC filed Critical Opko Ireland Global Holdings Ltd

2018-05-29 Application granted granted Critical

2018-05-29 Publication of ES2670029T3 publication Critical patent/ES2670029T3/es

Status Active legal-status Critical Current

2027-06-21 Anticipated expiration legal-status Critical

Links

QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 title claims abstract description 269
229930003316 Vitamin D Natural products 0.000 title claims abstract description 250
235000019166 vitamin D Nutrition 0.000 title claims abstract description 250
239000011710 vitamin D Substances 0.000 title claims abstract description 250
229940046008 vitamin d Drugs 0.000 title claims abstract description 250
150000003710 vitamin D derivatives Chemical class 0.000 title claims abstract description 219
229940088597 hormone Drugs 0.000 title claims abstract description 93
239000005556 hormone Substances 0.000 title claims abstract description 93
238000002560 therapeutic procedure Methods 0.000 title claims abstract description 40
239000003795 chemical substances by application Substances 0.000 title claims description 9
150000001875 compounds Chemical class 0.000 claims abstract description 70
238000000034 method Methods 0.000 claims abstract description 63
238000011282 treatment Methods 0.000 claims abstract description 55
208000020832 chronic kidney disease Diseases 0.000 claims abstract description 47
239000003814 drug Substances 0.000 claims abstract description 31
206010047626 Vitamin D Deficiency Diseases 0.000 claims abstract description 23
238000002657 hormone replacement therapy Methods 0.000 claims abstract description 23
229940079593 drug Drugs 0.000 claims abstract description 14
239000003668 hormone analog Substances 0.000 claims abstract 4
235000021318 Calcifediol Nutrition 0.000 claims description 110
JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 claims description 96
210000002966 serum Anatomy 0.000 claims description 92
102000003982 Parathyroid hormone Human genes 0.000 claims description 66
108090000445 Parathyroid hormone Proteins 0.000 claims description 66
210000004369 blood Anatomy 0.000 claims description 66
239000008280 blood Substances 0.000 claims description 66
239000000199 parathyroid hormone Substances 0.000 claims description 66
229960001319 parathyroid hormone Drugs 0.000 claims description 66
-1 vitamin D compounds Chemical class 0.000 claims description 52
GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 claims description 40
JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 claims description 37
JWUBBDSIWDLEOM-DCHLRESJSA-N 25-Hydroxyvitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C/C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DCHLRESJSA-N 0.000 claims description 37
JWUBBDSIWDLEOM-NQZHSCJISA-N 25-hydroxy-3 epi cholecalciferol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@H](O)CCC1=C JWUBBDSIWDLEOM-NQZHSCJISA-N 0.000 claims description 37
230000036765 blood level Effects 0.000 claims description 34
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 27
239000011575 calcium Substances 0.000 claims description 27
229910052791 calcium Inorganic materials 0.000 claims description 27
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 25
239000011574 phosphorus Substances 0.000 claims description 25
229910052698 phosphorus Inorganic materials 0.000 claims description 25
MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 25
MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims description 24
229960002061 ergocalciferol Drugs 0.000 claims description 24
235000001892 vitamin D2 Nutrition 0.000 claims description 24
239000011653 vitamin D2 Substances 0.000 claims description 24
230000007423 decrease Effects 0.000 claims description 22
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 21
235000005282 vitamin D3 Nutrition 0.000 claims description 19
239000011647 vitamin D3 Substances 0.000 claims description 19
229940021056 vitamin d3 Drugs 0.000 claims description 19
238000004519 manufacturing process Methods 0.000 claims description 18
238000011278 co-treatment Methods 0.000 claims description 15
239000012729 immediate-release (IR) formulation Substances 0.000 claims description 13
238000013270 controlled release Methods 0.000 claims description 12
230000001629 suppression Effects 0.000 claims description 12
KJKIIUAXZGLUND-ICCVIKJNSA-N 25-hydroxyvitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C KJKIIUAXZGLUND-ICCVIKJNSA-N 0.000 claims description 11
238000002347 injection Methods 0.000 claims description 9
239000007924 injection Substances 0.000 claims description 9
201000005991 hyperphosphatemia Diseases 0.000 claims description 8
239000006186 oral dosage form Substances 0.000 claims description 8
ZGLHBRQAEXKACO-XJRQOBMKSA-N 1alpha,25-dihydroxyvitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C ZGLHBRQAEXKACO-XJRQOBMKSA-N 0.000 claims description 7
239000002552 dosage form Substances 0.000 claims description 7
208000037147 Hypercalcaemia Diseases 0.000 claims description 6
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 6
230000000148 hypercalcaemia Effects 0.000 claims description 6
230000008416 bone turnover Effects 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
229960005084 calcitriol Drugs 0.000 claims description 4
GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 claims description 3
230000000737 periodic effect Effects 0.000 claims description 3
230000002092 calcimimetic effect Effects 0.000 claims description 2
239000002694 phosphate binding agent Substances 0.000 claims description 2
230000036470 plasma concentration Effects 0.000 claims description 2
239000000203 mixture Substances 0.000 description 42
238000009472 formulation Methods 0.000 description 31
208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 24
230000003834 intracellular effect Effects 0.000 description 14
238000012423 maintenance Methods 0.000 description 14
239000002775 capsule Substances 0.000 description 12
102100036285 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial Human genes 0.000 description 11
210000003734 kidney Anatomy 0.000 description 11
108010073030 25-Hydroxyvitamin D3 1-alpha-Hydroxylase Proteins 0.000 description 10
230000007812 deficiency Effects 0.000 description 9
210000004185 liver Anatomy 0.000 description 8
230000004075 alteration Effects 0.000 description 7
230000015556 catabolic process Effects 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
210000002990 parathyroid gland Anatomy 0.000 description 7
230000009467 reduction Effects 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
230000003111 delayed effect Effects 0.000 description 6
235000005911 diet Nutrition 0.000 description 6
239000007903 gelatin capsule Substances 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
238000013268 sustained release Methods 0.000 description 6
239000012730 sustained-release form Substances 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
238000011260 co-administration Methods 0.000 description 5
230000000694 effects Effects 0.000 description 5
230000036541 health Effects 0.000 description 5
239000002207 metabolite Substances 0.000 description 5
239000002243 precursor Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
230000002459 sustained effect Effects 0.000 description 5
108010004103 Chylomicrons Proteins 0.000 description 4
241000282412 Homo Species 0.000 description 4
206010021135 Hypovitaminosis Diseases 0.000 description 4
230000009102 absorption Effects 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
230000002411 adverse Effects 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
230000008859 change Effects 0.000 description 4
238000001514 detection method Methods 0.000 description 4
230000037213 diet Effects 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
238000005805 hydroxylation reaction Methods 0.000 description 4
229910052500 inorganic mineral Inorganic materials 0.000 description 4
230000003907 kidney function Effects 0.000 description 4
235000010755 mineral Nutrition 0.000 description 4
239000000047 product Substances 0.000 description 4
230000002035 prolonged effect Effects 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
230000028327 secretion Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
230000036561 sun exposure Effects 0.000 description 4
239000013589 supplement Substances 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
208000000412 Avitaminosis Diseases 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000004097 bone metabolism Effects 0.000 description 3
230000001276 controlling effect Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
235000015872 dietary supplement Nutrition 0.000 description 3
201000010099 disease Diseases 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
210000001842 enterocyte Anatomy 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
230000002440 hepatic effect Effects 0.000 description 3
235000006486 human diet Nutrition 0.000 description 3
208000030915 hypercalcemia disease Diseases 0.000 description 3
230000037041 intracellular level Effects 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
239000011707 mineral Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
238000009256 replacement therapy Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000032258 transport Effects 0.000 description 3
229940088594 vitamin Drugs 0.000 description 3
229930003231 vitamin Natural products 0.000 description 3
235000013343 vitamin Nutrition 0.000 description 3
239000011782 vitamin Substances 0.000 description 3
208000030401 vitamin deficiency disease Diseases 0.000 description 3
150000003722 vitamin derivatives Chemical class 0.000 description 3
208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 description 2
101150099181 Cyp27b1 gene Proteins 0.000 description 2
102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 2
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000012752 auxiliary agent Substances 0.000 description 2
235000021152 breakfast Nutrition 0.000 description 2
230000004094 calcium homeostasis Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
230000000378 dietary effect Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
230000001667 episodic effect Effects 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
230000029142 excretion Effects 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
235000014106 fortified food Nutrition 0.000 description 2
230000006870 function Effects 0.000 description 2
238000001631 haemodialysis Methods 0.000 description 2
230000000322 hemodialysis Effects 0.000 description 2
230000013632 homeostatic process Effects 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
210000003405 ileum Anatomy 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000031891 intestinal absorption Effects 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
239000002674 ointment Substances 0.000 description 2
230000011164 ossification Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
201000006409 renal osteodystrophy Diseases 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
229920000856 Amylose Polymers 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000283086 Equidae Species 0.000 description 1
DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
101000875401 Homo sapiens Sterol 26-hydroxylase, mitochondrial Proteins 0.000 description 1
101000855326 Homo sapiens Vitamin D 25-hydroxylase Proteins 0.000 description 1
206010020590 Hypercalciuria Diseases 0.000 description 1
201000002980 Hyperparathyroidism Diseases 0.000 description 1
206010020707 Hyperparathyroidism primary Diseases 0.000 description 1
208000013038 Hypocalcemia Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000029725 Metabolic bone disease Diseases 0.000 description 1
206010031149 Osteitis Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001494479 Pecora Species 0.000 description 1
YUGCAAVRZWBXEQ-UHFFFAOYSA-N Precholecalciferol Natural products C=1CCC2(C)C(C(C)CCCC(C)C)CCC2C=1C=CC1=C(C)CCC(O)C1 YUGCAAVRZWBXEQ-UHFFFAOYSA-N 0.000 description 1
201000000981 Primary Hyperparathyroidism Diseases 0.000 description 1
101100275586 Rattus norvegicus Cyp2j3 gene Proteins 0.000 description 1
229920000297 Rayon Polymers 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
241000978776 Senegalia senegal Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
102100036325 Sterol 26-hydroxylase, mitochondrial Human genes 0.000 description 1
102100026523 Vitamin D 25-hydroxylase Human genes 0.000 description 1
102000050760 Vitamin D-binding protein Human genes 0.000 description 1
101710179590 Vitamin D-binding protein Proteins 0.000 description 1
DIPPFEXMRDPFBK-UHFFFAOYSA-N Vitamin D4 Natural products C1CCC2(C)C(C(C)CCC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C DIPPFEXMRDPFBK-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
238000007792 addition Methods 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
230000008901 benefit Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
150000003938 benzyl alcohols Chemical class 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
208000018339 bone inflammation disease Diseases 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
235000020964 calcitriol Nutrition 0.000 description 1
239000011612 calcitriol Substances 0.000 description 1
230000003913 calcium metabolism Effects 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
UCTLRSWJYQTBFZ-DDPQNLDTSA-N cholesta-5,7-dien-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC=C21 UCTLRSWJYQTBFZ-DDPQNLDTSA-N 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
235000013345 egg yolk Nutrition 0.000 description 1
210000002969 egg yolk Anatomy 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
201000000523 end stage renal failure Diseases 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000008713 feedback mechanism Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229940013317 fish oils Drugs 0.000 description 1
235000013305 food Nutrition 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
230000002390 hyperplastic effect Effects 0.000 description 1
230000000705 hypocalcaemia Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
238000011545 laboratory measurement Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000000865 liniment Substances 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000003228 microsomal effect Effects 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
210000000885 nephron Anatomy 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
208000005368 osteomalacia Diseases 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
208000025061 parathyroid hyperplasia Diseases 0.000 description 1
239000002304 perfume Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
YUGCAAVRZWBXEQ-WHTXLNIXSA-N previtamin D3 Chemical compound C=1([C@@H]2CC[C@@H]([C@]2(CCC=1)C)[C@H](C)CCCC(C)C)\C=C/C1=C(C)CC[C@H](O)C1 YUGCAAVRZWBXEQ-WHTXLNIXSA-N 0.000 description 1
230000008569 process Effects 0.000 description 1
210000000512 proximal kidney tubule Anatomy 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000009103 reabsorption Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000009703 regulation of cell differentiation Effects 0.000 description 1
230000021014 regulation of cell growth Effects 0.000 description 1
230000036454 renin-angiotensin system Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000001932 seasonal effect Effects 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
DIPPFEXMRDPFBK-JPWDPSJFSA-N vitamin D4 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C DIPPFEXMRDPFBK-JPWDPSJFSA-N 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ES13177274.1T 2006-06-21 2007-06-21 Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D Active ES2670029T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US81514806P	2006-06-21	2006-06-21
US815148P		2006-06-21

Publications (1)

Publication Number	Publication Date
ES2670029T3 true ES2670029T3 (es)	2018-05-29

Family

ID=38895677

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
ES13177274.1T Active ES2670029T3 (es)	2006-06-21	2007-06-21	Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
ES18162510T Active ES2791535T3 (es)	2006-06-21	2007-06-21	Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
ES07840277.3T Active ES2497494T3 (es)	2006-06-21	2007-06-21	Método de tratamiento y prevención del hiperparatiroidismo secundario

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
ES18162510T Active ES2791535T3 (es)	2006-06-21	2007-06-21	Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
ES07840277.3T Active ES2497494T3 (es)	2006-06-21	2007-06-21	Método de tratamiento y prevención del hiperparatiroidismo secundario

Country Status (13)

Country	Link
US (5)	US8329677B2 (2)
EP (4)	EP3357496B1 (2)
JP (3)	JP5563296B2 (2)
CA (1)	CA2655499C (2)
CY (1)	CY1120675T1 (2)
DK (3)	DK2679228T3 (2)
ES (3)	ES2670029T3 (2)
HU (1)	HUE037309T2 (2)
LT (1)	LT2679228T (2)
PL (2)	PL2037936T3 (2)
PT (3)	PT2679228T (2)
SI (2)	SI2679228T1 (2)
WO (1)	WO2008008608A2 (2)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2593047T3 (es)	2006-02-03	2016-12-05	Opko Renal, Llc	Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
ES2670029T3 (es)	2006-06-21	2018-05-29	Opko Ireland Global Holdings, Ltd.	Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
US8592401B2 (en)	2007-04-25	2013-11-26	Proventiv Therapeutics, Llc	Methods and compounds for vitamin D therapy
HUE073014T2 (hu) *	2007-04-25	2025-12-28	Opko Renal Llc	Eljárás a másodlagos hyperparathyreoidismus biztonságos és hatékony kezelésére és megelõzésére krónikus vesebetegség esetén
US11752158B2 (en)	2007-04-25	2023-09-12	Eirgen Pharma Ltd.	Method of treating vitamin D insufficiency and deficiency
KR20190028822A (ko)	2007-04-25	2019-03-19	사이토크로마 인코포레이티드	비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
EP2281058B1 (en)	2008-04-02	2016-06-29	Opko Ireland Global Holdings, Ltd.	Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
EP2321273B1 (en) *	2008-07-24	2014-11-19	Wisconsin Alumni Research Foundation	Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration
WO2011123476A1 (en) *	2010-03-29	2011-10-06	Cytochroma Inc.	Methods and compositions for reducing parathyroid levels
EP2819749A4 (en) *	2012-03-01	2016-03-02	Univ Columbia	BIOMARKERS FOR AUTISM AND USES THEREOF
KR101847947B1 (ko)	2013-03-15	2018-05-28	옵코 아이피 홀딩스 Ⅱ 인코포레이티드	안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en)	2014-08-07	2019-03-05	Opko Ireland Global Holdings, Ltd.	Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
JP7032322B2 (ja)	2016-03-28	2022-03-08	オプコアイルランドグローバルホールディングスリミテッド	ビタミンｄ治療法
AU2019248829B2 (en)	2018-04-03	2025-02-06	Opko Ireland Global Holdings, Ltd.	Use of calcifediol in bariatric surgery patients
MX2020011741A (es) *	2019-02-06	2021-03-02	Eirgen Pharma Ltd	Método para controlar la evolución del hiperparatiroidismo mediante calcifediol, y composiciones para usarse en el mismo.
JP7408094B2 (ja) *	2020-04-27	2024-01-05	キョーラク株式会社	構造体
CN120694962A (zh) *	2020-05-31	2025-09-26	艾尔金制药有限公司	硬胶囊剂型和其用途
KR102666469B1 (ko)	2023-05-04	2024-05-17	주식회사 아리바이오	텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물
WO2025094144A1 (en)	2023-11-02	2025-05-08	Eirgen Pharma Ltd.	Controlling loss of kidney function

Family Cites Families (244)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3565924A (en)	1968-07-01	1971-02-23	Wisconsin Alumni Res Found	25-hydroxycholfcalciferol
US3833622A (en)	1969-03-17	1974-09-03	Upjohn Co	Crystalline 25-hydroxycholecalciferol hydrate and structurally related compounds
US3880894A (en)	1974-05-24	1975-04-29	Wisconsin Alumni Res Found	1,25-Dihydroxyergocalciferol
US4004003A (en)	1974-08-28	1977-01-18	The Upjohn Company	25-Hydroxycalciferol compounds for treatment of steroid-induced osteoporosis
US4335120A (en)	1979-03-21	1982-06-15	Hoffmann-La Roche Inc.	Administration of biologically active vitamin D3 and vitamin D2 materials
US4230701A (en)	1979-03-21	1980-10-28	Hoffmann-La Roche Inc.	Administration of biologically active vitamin D3 and vitamin D2 materials
JPS55139320A (en)	1979-04-16	1980-10-31	Teijin Ltd	Bone metabolism regulator
US4442093A (en)	1981-05-15	1984-04-10	Kureha Kagaku Kogyo Kabushiki Kaisha	Method for administering 24,25-dihydroxycholecalciferol to persons suffering from hypercalcemia
JPS57188520A (en)	1981-05-15	1982-11-19	Kureha Chem Ind Co Ltd	Antihyperkalemia
JPS5832823A (ja)	1981-08-20	1983-02-25	Chugai Pharmaceut Co Ltd	脱癌剤
JPS58206524A (ja)	1982-05-26	1983-12-01	Kureha Chem Ind Co Ltd	抗腫瘍剤
US4448721A (en)	1982-09-20	1984-05-15	Wisconsin Alumni Research Foundation	Hydroxyvitamin D2 compounds and process for preparing same
US4721613A (en)	1982-12-13	1988-01-26	Alza Corporation	Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
JPS59155309A (ja)	1983-02-22	1984-09-04	Teijin Ltd	活性型ビタミンｄ↓３類組成物
US4684524A (en)	1984-03-19	1987-08-04	Alza Corporation	Rate controlled dispenser for administering beneficial agent
US4555364A (en)	1984-11-01	1985-11-26	Wisconsin Alumni Research Foundation	Method for preparing 1-hydroxyvitamin D compounds
US4695591A (en)	1985-03-29	1987-09-22	Schering Corporation	Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4668517A (en)	1985-04-04	1987-05-26	Norwich Eaton Pharmaceuticals, Inc.	Furazolidone dosage form
DE3676235D1 (de)	1985-06-04	1991-01-31	Teijin Ltd	Arzneizubereitung mit verzoegerter wirkstoffabgabe.
JPS61293911A (ja)	1985-06-24	1986-12-24	Teisan Seiyaku Kk	徐放化製剤
US4892821A (en)	1987-07-08	1990-01-09	Taisho Pharmaceutical Co., Ltd.	Method for preparing vitamin D compounds
US4997824A (en)	1987-07-22	1991-03-05	Teva Pharmaceutical Industries Ltd.	Combination of cholecalciferol derivatives for the treatment of renal bone disease
US5602116A (en)	1988-08-02	1997-02-11	Bone Care International, Inc.	Method for treating and preventing secondary hyperparathyroidism
US5869473A (en)	1988-08-02	1999-02-09	Bone Care International, Inc.	Method for treating and preventing hyperparathyroidism
US5104864A (en)	1988-08-02	1992-04-14	Bone Care International, Inc.	Method for treating and preventing loss of bone mass
JP2893191B2 (ja)	1988-11-08	1999-05-17	武田薬品工業株式会社	放出制御性マトリックス剤
JP2525478B2 (ja)	1989-03-01	1996-08-21	帝人株式会社	安定性の改良された活性型ビタミンｄ▲下３▼類固型製剤
JPH02240024A (ja)	1989-03-13	1990-09-25	Ss Pharmaceut Co Ltd	活性型ビタミンｄ↓３類製剤用組成物
US5026559A (en)	1989-04-03	1991-06-25	Kinaform Technology, Inc.	Sustained-release pharmaceutical preparation
GB9004544D0 (en)	1990-03-01	1990-04-25	Leo Pharm Prod Ltd	Novel treatment ii
JP2845342B2 (ja)	1990-04-28	1999-01-13	大正製薬株式会社	ビタミンｄ▲下３▼誘導体含有固形製剤組成物
JPH04198129A (ja)	1990-11-28	1992-07-17	Sumitomo Pharmaceut Co Ltd	活性型ビタミンｄ↓３類含有組成物
JP2893140B2 (ja)	1990-11-30	1999-05-17	エスエス製薬株式会社	安定なビタミンｄ製剤
JPH04288016A (ja)	1991-03-14	1992-10-13	Tokai Capsule Kk	活性型ビタミンｄ３類軟カプセル剤の製造方法
DE69214704T2 (de)	1991-04-09	1997-04-17	Takeda Chemical Industries Ltd	Stabilisiertes Vitamin D Arzneimittel
US5693615A (en)	1991-06-05	1997-12-02	The Procter & Gamble Company	Therapeutic compositions for osteoinduction
US6031003A (en)	1991-08-23	2000-02-29	Nps Pharmaceuticals, Inc.	Calcium receptor-active molecules
US6313146B1 (en)	1991-08-23	2001-11-06	Nps Pharmaceuticals, Inc.	Calcium receptor-active molecules
US6001884A (en)	1991-08-23	1999-12-14	Nps Pharmaceuticals, Inc.	Calcium receptor-active molecules
US6011068A (en)	1991-08-23	2000-01-04	Nps Pharmaceuticals, Inc.	Calcium receptor-active molecules
US5266331A (en)	1991-11-27	1993-11-30	Euroceltique, S.A.	Controlled release oxycodone compositions
US5472712A (en)	1991-12-24	1995-12-05	Euroceltique, S.A.	Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5160742A (en)	1991-12-31	1992-11-03	Abbott Laboratories	System for delivering an active substance for sustained release
JP3722832B2 (ja)	1992-06-22	2005-11-30	ルーナー、コーポレーション	経口用１α−ヒドロキシプレビタミンＤ
US5795882A (en)	1992-06-22	1998-08-18	Bone Care International, Inc.	Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
US5354743A (en)	1992-09-15	1994-10-11	Thys Jacobs Susan	Method for the treatment of premenstrual syndrome with vitamin D
US5431917A (en)	1992-10-08	1995-07-11	Japan Elanco Company, Ltd.	Hard capsule for pharmaceutical drugs and method for producing the same
US5342626A (en)	1993-04-27	1994-08-30	Merck & Co., Inc.	Composition and process for gelatin-free soft capsules
JP2684587B2 (ja)	1993-06-21	1997-12-03	呉羽化学工業株式会社	腎性骨異栄養症における骨量減少抑制剤
US6121469A (en)	1993-12-23	2000-09-19	The Regents Of The University Of California	Therapeutically effective 1α,25-dihydroxyvitamin D3 analogs
JPH07242550A (ja) *	1994-03-02	1995-09-19	Teijin Ltd	二次性副甲状腺機能亢進症治療剤
IL110117A0 (en)	1994-06-24	1994-10-07	Univ Ben Gurion	Pharmaceutical compositions comprising vitamin-d analogs
SE9402422D0 (sv)	1994-07-08	1994-07-08	Astra Ab	New beads for controlled release and a pharmaceutical preparation containing the same
WO1996003113A1 (en)	1994-07-22	1996-02-08	G.D. Searle & Co.	Self-emulsifying drug delivery system
JPH0892098A (ja)	1994-09-27	1996-04-09	Teijin Ltd	肺結核治療剤
ES2285707T3 (es)	1994-10-21	2007-11-16	Nps Pharmaceuticals, Inc.	Compuestos activos frente al receptor de calcio.
US5756123A (en)	1994-12-01	1998-05-26	Japan Elanco Co., Ltd.	Capsule shell
US6242434B1 (en)	1997-08-08	2001-06-05	Bone Care International, Inc.	24-hydroxyvitamin D, analogs and uses thereof
US6376479B1 (en)	1995-04-03	2002-04-23	Bone Care International, Inc.	Method for treating and preventing hyperparathyroidism
US20020183288A1 (en)	1995-04-03	2002-12-05	Bone Care International, Inc.	Method for treating and preventing hyperparathyroidism
US20040043971A1 (en)	1995-04-03	2004-03-04	Bone Care International, Inc.	Method of treating and preventing hyperparathyroidism with active vitamin D analogs
JP3372259B2 (ja)	1995-09-21	2003-01-27	ウィスコンシン・アルムニ・リサーチ・ファウンデーション	カルシトリオール誘導体およびそれらの用途
DE19549243A1 (de)	1995-12-21	1997-06-26	Schering Ag	Pharmazeutische Präparate enthaltend Clathrate von Cyclodextrinen und nichtnatürliche Vitamin D-Analoga
NO971934L (no)	1996-05-23	1997-11-24	Hoffmann La Roche	Flourinerte vitamin D3 -analoger
US5939408A (en)	1996-05-23	1999-08-17	Hoffman-La Roche Inc.	Vitamin D3 analogs
AU3868997A (en)	1996-08-26	1998-03-19	Takeda Chemical Industries Ltd.	Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
US5958451A (en)	1996-09-03	1999-09-28	Yung Shin Pharm Ind. Co., Ltd.	Process for producing porous, controlled-release capsules and encapsulated composition
US5976784A (en)	1996-09-20	1999-11-02	Wisconsin Alumni Research Foundation	Calcitriol derivatives and their uses
US8828432B2 (en)	1996-10-28	2014-09-09	General Mills, Inc.	Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
CA2269806C (en)	1996-10-28	2006-01-24	Bernhard H. Van Lengerich	Embedding and encapsulation of controlled release particles
JPH10158171A (ja)	1996-12-02	1998-06-16	Kita:Kk	ビタミンｄ化合物を配合した眼内投与剤
US20020128240A1 (en)	1996-12-30	2002-09-12	Bone Care International, Inc.	Treatment of hyperproliferative diseases using active vitamin D analogues
US6503893B2 (en)	1996-12-30	2003-01-07	Bone Care International, Inc.	Method of treating hyperproliferative diseases using active vitamin D analogues
US20030129194A1 (en)	1997-02-13	2003-07-10	Bone Care International, Inc.	Targeted therapeutic delivery of vitamin D compounds
US6034075A (en)	1997-03-20	2000-03-07	The Trustees Of Columbia University In The City Of New York	Method of treating polycystic ovarian syndrome
US5872113A (en)	1997-05-16	1999-02-16	Syntex (U.S.A.) Inc.	Fluorinated vitamin D3 analogs
PT1009387E (pt)	1997-07-02	2006-08-31	Euro Celtique Sa	Formulacoes estabilizadas de libertacao controlada de tramadol
JPH1175863A (ja)	1997-07-10	1999-03-23	Kyowa Hakko Kogyo Co Ltd	２５−ヒドロキシビタミンＤ３−１α−水酸化酵素および該酵素をコードするＤＮＡ
US6096876A (en)	1997-08-06	2000-08-01	Shriners Hospitals For Children	1-α-hydroxylase materials and methods
WO1999011272A1 (en)	1997-09-02	1999-03-11	Johns Hopkins University School Of Medicine	Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
US5919986A (en)	1997-10-17	1999-07-06	Hoffmann-La Roche Inc.	D-homo vitamin D3 derivatives
JPH11158074A (ja)	1997-12-03	1999-06-15	Hayashi Tomie	高アミノ酸付加活性型ビタミンｄ強化組成物
US20030059471A1 (en)	1997-12-15	2003-03-27	Compton Bruce Jon	Oral delivery formulation
CA2323782A1 (en) *	1998-03-25	1999-09-30	Cutanogen, Inc.	Methods for prevention and treatment of cancer
ES2368824T3 (es) *	1998-03-27	2011-11-22	Oregon Health & Science University	Vitamina d y sus análogos en el tratamiento de tumores y otros desórdenes hiperproliferativos.
US6197340B1 (en)	1998-05-28	2001-03-06	Medical Research Institute	Controlled release lipoic acid
US8133694B2 (en)	1998-06-25	2012-03-13	Immundiagnostik Ag	Functional vitamin D derivatives and method of determining 25-hydroxy- and 1α, 25-dihydroxy vitamin D
US6214376B1 (en)	1998-08-25	2001-04-10	Banner Pharmacaps, Inc.	Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture
DE69942928D1 (de)	1998-08-27	2010-12-23	Pfizer Health Ab	Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung
SE9803871D0 (sv)	1998-11-11	1998-11-11	Pharmacia & Upjohn Ab	Therapeutic method and formulation
US6139875A (en)	1998-09-29	2000-10-31	Eastman Chemical Company	Aqueous enteric coating composition and low gastric permeability enteric coating
EP2266542A3 (en)	1998-10-01	2013-07-31	Elan Pharma International Limited	Controlled release nanoparticulate compositions
ATE429813T1 (de)	1998-10-09	2009-05-15	Gen Mills Inc	Verkapselung empfindlicher flüssiger komponenten in eine matrix zur gewinnung diskreter lagerbeständiger partikel
JP3449253B2 (ja)	1998-10-29	2003-09-22	シオノギクオリカプス株式会社	硬質カプセルの製造方法
JP2000206312A (ja)	1998-11-12	2000-07-28	Olympus Optical Co Ltd	光学素子
PT1140012E (pt)	1998-12-17	2004-05-31	Alza Corp	Conversao de capsulas de gelatina cheias com liquido em sistemas de libertacao controlada por camadas multiplas
US6342249B1 (en)	1998-12-23	2002-01-29	Alza Corporation	Controlled release liquid active agent formulation dosage forms
US6432936B1 (en)	1999-01-20	2002-08-13	Wisconsin Alumni Research Foundation	Crystalline 1α-hydroxyvitamin D2 and method of purification thereof
US6248363B1 (en)	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1745787B1 (en)	1999-04-01	2016-11-09	Johns Hopkins University	NON-CALCEMIC, ANTIPROLIFERATIVE, TRANSCRIPTIONALLY ACTIVE SULFUR-CONTAINING ANALOGS OF 1-alpha 25-DIHYDROXY VITAMIN D3
US7648826B1 (en)	1999-04-02	2010-01-19	The Regents Of The University Of California	Detecting CYP24 expression level as a marker for predisposition to cancer
DE19916419B4 (de)	1999-04-08	2005-06-16	Schering Ag	Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
WO2000072831A1 (en)	1999-05-27	2000-12-07	Drugtech Corporation	Nutritional formulations
US6340473B1 (en)	1999-07-07	2002-01-22	R.P. Scherer Technologies, Inc.	Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
US6051567A (en)	1999-08-02	2000-04-18	Abbott Laboratories	Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
US6274169B1 (en)	1999-08-02	2001-08-14	Abbott Laboratories	Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
CN1179725C (zh)	1999-08-31	2004-12-15	中外制药株式会社	软胶囊剂
US20060034937A1 (en)	1999-11-23	2006-02-16	Mahesh Patel	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0007419D0 (en)	2000-03-27	2000-05-17	Smithkline Beecham Gmbh	Composition
US6375981B1 (en)	2000-06-01	2002-04-23	A. E. Staley Manufacturing Co.	Modified starch as a replacement for gelatin in soft gel films and capsules
AU7895601A (en)	2000-07-18	2002-01-30	Bone Care Int Inc	Stabilized 1alpha-hydroxy vitamin d
US6491950B1 (en)	2000-08-07	2002-12-10	Kos Pharmaceuticals, Inc.	Controlled release pharmaceutical composition
US6967026B2 (en)	2000-08-29	2005-11-22	Nisshin Kasel Co., Ltd.	Hard capsule
US6887493B2 (en)	2000-10-25	2005-05-03	Adi Shefer	Multi component controlled release system for oral care, food products, nutraceutical, and beverages
AU2738302A (en)	2000-10-30	2002-05-15	Euro Celtique Sa	Controlled release hydrocodone formulations
US6479649B1 (en)	2000-12-13	2002-11-12	Fmc Corporation	Production of carrageenan and carrageenan products
JP2002302447A (ja)	2001-04-03	2002-10-18	Shimizu Pharmaceutical Co Ltd	局所投与用癌治療剤
CA2446957A1 (en)	2001-05-15	2002-11-21	Warner-Lambert Company Llc	Compaction process for manufacture of sodium phenytoin dosage form
WO2003004003A1 (fr)	2001-07-05	2003-01-16	Wakunaga Pharmaceutical Co., Ltd.	Capsules molles
US6870833B2 (en)	2001-07-20	2005-03-22	Net2Phone, Inc.	Active voice messaging
US7166585B2 (en)	2001-08-22	2007-01-23	Cytochroma Inc.	24-Sulfur-substituted analogs of 1α,25-dihydroxy vitamin D3
US7033996B2 (en)	2001-08-31	2006-04-25	University Of Medicine & Dentistry Of New Jersey	Method for the treatment of vitamin D related disease
DE10149674A1 (de)	2001-10-09	2003-04-24	Apogepha Arzneimittel Gmbh	Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
ES2283593T3 (es)	2001-10-12	2007-11-01	Johns Hopkins University	Analogos de oxima poco calcemicos de 1alfa,25-dihidroxi vitamina d3.
US6524788B1 (en)	2001-11-02	2003-02-25	Thomas L. Cantor	Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
US7056655B2 (en)	2001-11-02	2006-06-06	Scantibodies Laboratory, Inc.	Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
ITMI20012366A1 (it)	2001-11-09	2003-05-09	Farmatron Ltd	Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
DE60238269D1 (de)	2001-11-22	2010-12-23	Morishita Jintan Co	Nicht-gelatinöse Kapseln
GB0128415D0 (en)	2001-11-27	2002-01-16	Univ Sheffield	Medicaments
JP2005515996A (ja)	2001-12-03	2005-06-02	ノバセアインコーポレイティッド	活性型ビタミンｄ化合物を含む薬学的組成物
US6627622B2 (en)	2002-02-18	2003-09-30	Wisconsin Alumni Research Foundation	(20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
FR2829142B1 (fr)	2001-12-27	2004-02-13	Ulice	Composition filmogene d'heteroxylanes pour la fabrication de capsules ainsi obtenues
US7632518B2 (en)	2002-01-15	2009-12-15	Dsm Ip Assets B.V.	25-hydroxy vitamin D3 compositions
US6949256B2 (en)	2002-01-18	2005-09-27	Banner Pharmacaps, Inc.	Non-gelatin capsule shell formulation
NO20021592D0 (no)	2002-04-04	2002-04-04	Fmc Biopolymer As	Polysakkaridkapsler og fremgangsmåte ved fremstilling derav
CA2480814A1 (en)	2002-04-05	2003-10-23	Merck & Co., Inc.	Method for inhibiting bone resorption with an alendronate and vitamin d formulation
JP2005528383A (ja)	2002-04-10	2005-09-22	ミラー，フレッド，エイチ．	多重相・複数コンパートメントカプセルシステム
US7288407B2 (en)	2002-05-02	2007-10-30	Cytochroma, Inc.	Stable cytochrome P450 24 (CYP24) expressing cell line and methods and uses thereof
US7101865B2 (en)	2002-06-13	2006-09-05	Cytochroma Inc.	24-sulfoximine vitamin D3 compounds
MXPA05000128A (es)	2002-07-05	2005-09-30	Temrel Inc	Composicion de liberacion controlada.
TWI336260B (en)	2002-07-25	2011-01-21	Glaxo Group Ltd	Dosage form suitable for retaining drug substance
NZ570198A (en)	2002-07-29	2010-01-29	Alza Corp	Methods and dosage forms for controlled delivery of paliperidone or risperidone
US8268352B2 (en)	2002-08-05	2012-09-18	Torrent Pharmaceuticals Limited	Modified release composition for highly soluble drugs
AU2002368245A1 (en)	2002-09-26	2004-04-19	Young-Kweon Choi	Matrix type patch for transdermal administration of vitamin d analog and the use thereof
US20050101576A1 (en)	2003-11-06	2005-05-12	Novacea, Inc.	Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US8999372B2 (en)	2002-11-14	2015-04-07	Cure Pharmaceutical Corporation	Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
JP2004175750A (ja)	2002-11-28	2004-06-24	Kose Corp	皮膚障害抑制剤、皮膚障害改善剤、及びそれらを含有する皮膚外用剤
US20050026877A1 (en)	2002-12-03	2005-02-03	Novacea, Inc.	Pharmaceutical compositions comprising active vitamin D compounds
AU2003300984A1 (en)	2002-12-16	2004-07-22	Teva Pharmaceutical Industries Ltd.	Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative
US8106035B2 (en)	2002-12-18	2012-01-31	Cytochroma Inc.	25-SO2-substituted analogs of 1μ,25-dihydroxyvitamin D3
US20040197407A1 (en)	2003-02-11	2004-10-07	Ramkumar Subramanian	Methods and dosage forms with modified layer geometry
US7816341B2 (en)	2003-04-14	2010-10-19	Fmc Corporation	Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom
JP2007525451A (ja)	2003-04-14	2007-09-06	エフ　エム　シー　コーポレーション	均一かつ熱可逆性アルギネートフィルムの伝達システム
WO2004098507A2 (en)	2003-04-30	2004-11-18	Bioxell S.P.A.	1,3 aclyated 24-keto-vitamin d3 compounds and methods of use thereof
AU2004237437B2 (en)	2003-05-07	2011-01-20	Osteologix A/S	Controlled release composition containing a strontium salt
EP1479677A1 (en)	2003-05-19	2004-11-24	Aventis Pharma Deutschland GmbH	New indole derivatives as factor xa inhibitors
JP2007526013A (ja)	2003-06-16	2007-09-13	ソルクスインコーポレイテッド	緑内障を治療するためのシャント装置
JP5628467B2 (ja)	2003-06-26	2014-11-19	シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａＵｓ，Ｉｎｃ．	生体分解性徐放性ドラッグデリバリーシステム
AU2003903382A0 (en)	2003-07-03	2003-07-17	Medvet Science Pty Ltd	Inhibition of calcitriol mediated cyp24 induction screening for compounds therefor and uses thereof
CN1816324A (zh)	2003-07-04	2006-08-09	尼克麦德丹麦公司	口服用的含甲状旁腺激素(pth)的药物组合物
US20050148557A1 (en)	2003-07-29	2005-07-07	Jin Tian	Use of Vitamin Ds to treat kidney disease
US20050124591A1 (en)	2003-07-29	2005-06-09	Jin Tian	Use of vitamin Ds to treat kidney disease
PT3395338T (pt)	2003-09-12	2019-07-23	Amgen Inc	Formulação de dissolução rápida de cinacalcet hcl
US7053075B2 (en)	2003-11-25	2006-05-30	Deluca Hector F	Methods for reducing body fat using vitamin D compounds
US7427670B2 (en)	2003-12-19	2008-09-23	Cytochroma Inc.	Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof
US20060009425A1 (en)	2004-05-28	2006-01-12	Leticia Delgado-Herrera	Oral formulations of paricalcitol
WO2005123120A1 (en)	2004-06-16	2005-12-29	Smart Drug Systems Inc.	Sustained release vaccine composition
US20050287213A1 (en)	2004-06-28	2005-12-29	Wong Patrick S	Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents
US20060019933A1 (en)	2004-07-22	2006-01-26	David Boardman	Process for preparing stabilized vitamin D
WO2006010640A1 (en)	2004-07-29	2006-02-02	Sanofi-Aventis	Pharmaceutical multilayer tablet for controlled release of active ingredients with highly ph-dependent solubility
US8231896B2 (en)	2004-11-08	2012-07-31	R.P. Scherer Technologies, Llc	Non-gelatin soft capsule system
AU2004325362B2 (en)	2004-12-03	2012-09-06	Council Of Scientific And Industrial Research	Process of preparation of biodegradable films from semi refined kappa carrageenan
US8318210B2 (en)	2005-02-28	2012-11-27	Neos Therapeutics, Lp	Compositions and methods of making sustained release liquid formulations
US7745226B2 (en)	2005-04-06	2010-06-29	Quest Diagnostics Investments Incorporated	Methods for detecting vitamin D metabolites
CA2604943C (en)	2005-04-15	2013-09-17	Clarus Therapeutics, Inc.	Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US20060257481A1 (en)	2005-04-21	2006-11-16	Decode Genetics Ehf.	Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy
US9205047B2 (en)	2005-04-25	2015-12-08	The Governing Council Of The University Of Toronto	Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
US20080134937A1 (en)	2005-05-25	2008-06-12	Joo Hwan Yang	Cellulose hard capsule enhancing mechanical film strength
AR055099A1 (es)	2005-07-28	2007-08-08	Alza Corp	Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
CN101273062A (zh)	2005-09-29	2008-09-24	霍夫曼-拉罗奇有限公司	抗25-羟基维生素d的抗体
ITFI20050206A1 (it)	2005-09-30	2007-04-01	Valpharma Sa	Composizione farmaceutica a rilascio controllato di venlafaxina cloridrato, e processo per la sua preparazione
CA2624897C (en)	2005-10-12	2017-02-14	Proventiv Therapeutics, Llc	Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
CA2627292C (en)	2005-10-26	2012-04-17	Banner Pharmacaps, Inc.	Hydrophilic vehicle-based dual controlled release matrix system
CN101351196B (zh)	2005-10-26	2013-07-03	班纳制药公司	作为胶囊填充物的基于亲脂性载体的双重控释基质系统
WO2007053612A2 (en)	2005-11-01	2007-05-10	Harding, Nancy, E.	High viscosity diutan gums and methods of producing
WO2007068287A1 (en)	2005-12-15	2007-06-21	Laboratoria Qualiphar	Sustained release vitamin preparation
MXPA05014091A (es)	2005-12-20	2007-06-20	Leopoldo De Jesus Espinosa Abdala	Composiciones farmaceuticas que comprenden derivados de esteroides sinteticos, minerales y el metabolito activo de la vitamina d, 1,25(oh)2d3 (calcitriol) para la prevencion y tratamiento de la osteoporosis y el control de los sintomas de la menopaus
CA2638909A1 (en)	2006-01-31	2007-08-16	Health Research Inc.	Method for identifying altered vitamin d metabolism
US7528122B2 (en)	2006-02-02	2009-05-05	Wisconsin Alumni Research Foundation	Vitamin D analog—NEL, methods and uses thereof
ES2593047T3 (es)	2006-02-03	2016-12-05	Opko Renal, Llc	Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
GB0606426D0 (en)	2006-03-30	2006-05-10	Novartis Ag	Benzimidazole derivatives
WO2007146004A1 (en)	2006-06-06	2007-12-21	Fmc Corporation	Kappa-2 carrageenan composition and products made therefrom
US20080109983A1 (en)	2006-11-10	2008-05-15	Kegel, Llc	Zero Turning Radius Lane Maintenance Machine
ES2670029T3 (es) *	2006-06-21	2018-05-29	Opko Ireland Global Holdings, Ltd.	Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
EP1912400A1 (en)	2006-10-10	2008-04-16	Matsushita Electric Industrial Co., Ltd.	Method and apparatus for mobile IP route optimization
CN101595133B (zh)	2006-10-27	2012-11-14	比利时胶囊公司	羟丙基甲基纤维素硬胶囊及制备方法
US8501717B2 (en)	2007-02-09	2013-08-06	Merck, Sharp & Dohme Corp.	Methods to treat and/or prevent mucositis
US8491937B2 (en)	2007-02-15	2013-07-23	Wyeth Llc	Stability in vitamin and mineral supplements
US7893357B2 (en)	2007-03-20	2011-02-22	Electrolock, Inc.	Roebel winding with conductive felt
EP2136814A4 (en)	2007-03-21	2012-05-30	Univ Duke	MEDICAL KITS AND FORMULATIONS FOR PREVENTING, TREATING OR REDUCING SECONDARY FRACTURES FROM A PREVIOUS FRACTURE
US8592401B2 (en)	2007-04-25	2013-11-26	Proventiv Therapeutics, Llc	Methods and compounds for vitamin D therapy
KR20190028822A (ko)	2007-04-25	2019-03-19	사이토크로마 인코포레이티드	비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
HUE073014T2 (hu)	2007-04-25	2025-12-28	Opko Renal Llc	Eljárás a másodlagos hyperparathyreoidismus biztonságos és hatékony kezelésére és megelõzésére krónikus vesebetegség esetén
US11752158B2 (en)	2007-04-25	2023-09-12	Eirgen Pharma Ltd.	Method of treating vitamin D insufficiency and deficiency
US20090004284A1 (en)	2007-06-26	2009-01-01	Watson Pharmaceuticals, Inc.	Controlled release tamsulosin hydrochloride formulation
KR100836960B1 (ko)	2007-09-07	2008-06-10	주식회사 서울제약	새로운 나이아신 제어방출형 제제
EP2042165A1 (de)	2007-09-28	2009-04-01	Swiss Caps Rechte und Lizenzen AG	Hot-Melt-Befüllte Weichkapseln
US20090155355A1 (en)	2007-12-12	2009-06-18	Multi Formulations Ltd.	Particles in a capsule
JP5593550B2 (ja)	2008-02-13	2014-09-24	ディーエスエムアイピーアセッツビー．ブイ．	ヒトの筋生理に影響を与えるための２５−ヒドロキシビタミンｄ３の使用
KR20100126375A (ko)	2008-02-13	2010-12-01	디에스엠 아이피 어셋츠 비.브이.	비타민 ｄ와 25-하이드록시비타민 ｄ3의 조합물
EA019348B1 (ru)	2008-02-13	2014-03-31	ДСМ АйПи АССЕТС Б.В.	Способ лечения гипергликемии комбинацией 25-гидроксивитамина d3 и витамина d
JP2011511826A (ja)	2008-02-13	2011-04-14	ディーエスエムアイピーアセッツビー．ブイ．	２５−ヒドロキシビタミンｄ３を用いた高血圧症の治療
MX2010008906A (es)	2008-02-13	2010-11-05	Dsm Ip Assets Bv	Uso combinado de 25-hidroxi-vitamina d3 y vitamina d3 para mejorar la densidad mineral osea y para tratar osteoporosis.
EP2281058B1 (en)	2008-04-02	2016-06-29	Opko Ireland Global Holdings, Ltd.	Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
EP2321273B1 (en)	2008-07-24	2014-11-19	Wisconsin Alumni Research Foundation	Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration
WO2010034342A1 (en)	2008-09-24	2010-04-01	Evonik Röhm Gmbh	Ph-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol
ES2425762T3 (es)	2008-10-27	2013-10-17	Roquette Freres	Polímero insoluble en agua: revestimientos de película a base de derivados de almidón modificado para la liberación dirigida al colon
SG196810A1 (en)	2009-01-23	2014-02-13	Acraf	Controlled release pharmaceutical or foodformulation and process for its preparation
CH700543A2 (de)	2009-03-03	2010-09-15	Innogel Ag	Film auf Basis von Stärke.
WO2011031617A2 (en)	2009-09-10	2011-03-17	Fmc Corporation	Seamless alginate capsules
IT1396937B1 (it)	2009-11-26	2012-12-20	Bruzzese	Formulazioni di bisfosfonati e vitamina d idonee alla somministrazione intermittente per via intramuscolare e sottocutanea
FR2953139B1 (fr)	2009-11-27	2012-04-13	Servier Lab	Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
US8101204B2 (en)	2010-01-14	2012-01-24	Karl Wei Cao	Hard capsule composition and method of use
US8101203B2 (en)	2010-01-14	2012-01-24	Karl Wei Cao	Hard capsule composition and method of use
WO2011095388A1 (en)	2010-02-04	2011-08-11	Synthon Bv	Tolterodine bead
WO2011123476A1 (en)	2010-03-29	2011-10-06	Cytochroma Inc.	Methods and compositions for reducing parathyroid levels
KR20120005228A (ko)	2010-07-08	2012-01-16	주식회사 네비팜	골다공증 치료용 비스포스폰산 함유 장용 약학조성물 및 그의 제조방법
KR101288079B1 (ko)	2010-08-04	2013-07-22	알.피.쉐러 테크놀러지즈 엘엘씨	연질캡슐용 막 형성 조성물
US20120135103A1 (en)	2010-11-30	2012-05-31	Mead Johnson Nutrition Company	Staged Infant Feeding Regimen To Promote Healthy Development And Growth
BR112013011259B1 (pt)	2010-12-06	2020-03-03	Dsm Ip Assets Bv	Uso de 25-hidroxivitamina D3 para a fabricação de um produto farmacêutico, alimento, ou nutracêutico para manter níveis saudáveis de eotaxina
ES2614817T3 (es)	2010-12-28	2017-06-02	Future Diagnostics B.V.	Reactivo de liberación para vitamina D
CA2860284C (en)	2011-03-02	2019-02-05	D3 Pharma Limited	Vitamin d composition
ES2617654T3 (es)	2011-04-20	2017-06-19	Suheung Co., Ltd.	Composición de la cubierta de cápsula blanda de origen no animal que tiene dureza de la cubierta y desintegración, mejoradas
CA2833633A1 (en)	2011-04-20	2012-10-26	Jason Fisher	Composition and method for enhancing an immune response
CN102771688A (zh)	2011-05-13	2012-11-14	富曼实（上海）商贸有限公司	可食用液体填充的多糖胶囊
US20130085121A1 (en)	2011-09-30	2013-04-04	Jianguo Wang	Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d
WO2014029953A1 (en)	2012-08-21	2014-02-27	Cipla Limited	Hot melt extruded (hme) pharmaceutical composition of cinacalcet
KR101847947B1 (ko)	2013-03-15	2018-05-28	옵코 아이피 홀딩스 Ⅱ 인코포레이티드	안정화되고 변형된 비타민 ｄ 방출 제형
PT106978A (pt)	2013-05-31	2014-12-02	Tecnimede Sociedade Tecnico Medicinal S A	Composição sólida oral contendo ácido ibandrónico e vitamina d
EP2815745A1 (en)	2013-06-21	2014-12-24	Swiss Caps Rechte und Lizenzen AG	Soft shell capsule and process for its manufacture
CN103495176B (zh)	2013-10-26	2015-01-28	中山市凯博思淀粉材料科技有限公司	一种共混挤出法制备淀粉基软胶囊的方法
CN103520133B (zh)	2013-10-26	2015-02-04	中山市凯博思淀粉材料科技有限公司	一种淀粉基软胶囊的制备方法
US10220047B2 (en)	2014-08-07	2019-03-05	Opko Ireland Global Holdings, Ltd.	Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
JP2017523220A (ja)	2014-08-07	2017-08-17	オプコアイルランドグローバルホールディングスリミテッド	２５−ヒドロキシビタミンｄを用いる補助的療法

2007
- 2007-06-21 ES ES13177274.1T patent/ES2670029T3/es active Active
- 2007-06-21 DK DK13177274.1T patent/DK2679228T3/en active
- 2007-06-21 PL PL07840277T patent/PL2037936T3/pl unknown
- 2007-06-21 EP EP18162510.4A patent/EP3357496B1/en active Active
- 2007-06-21 WO PCT/US2007/071791 patent/WO2008008608A2/en not_active Ceased
- 2007-06-21 PT PT131772741T patent/PT2679228T/pt unknown
- 2007-06-21 DK DK07840277.3T patent/DK2037936T3/da active
- 2007-06-21 PT PT181625104T patent/PT3357496T/pt unknown
- 2007-06-21 ES ES18162510T patent/ES2791535T3/es active Active
- 2007-06-21 EP EP20151076.5A patent/EP3659608A1/en active Pending
- 2007-06-21 LT LTEP13177274.1T patent/LT2679228T/lt unknown
- 2007-06-21 SI SI200732029T patent/SI2679228T1/en unknown
- 2007-06-21 PT PT78402773T patent/PT2037936E/pt unknown
- 2007-06-21 JP JP2009516725A patent/JP5563296B2/ja not_active Expired - Fee Related
- 2007-06-21 SI SI200731501T patent/SI2037936T1/sl unknown
- 2007-06-21 DK DK18162510.4T patent/DK3357496T3/da active
- 2007-06-21 EP EP13177274.1A patent/EP2679228B1/en active Active
- 2007-06-21 HU HUE13177274A patent/HUE037309T2/hu unknown
- 2007-06-21 CA CA2655499A patent/CA2655499C/en active Active
- 2007-06-21 US US12/305,572 patent/US8329677B2/en active Active
- 2007-06-21 EP EP07840277.3A patent/EP2037936B1/en active Active
- 2007-06-21 PL PL13177274T patent/PL2679228T3/pl unknown
- 2007-06-21 ES ES07840277.3T patent/ES2497494T3/es active Active
2012
- 2012-11-19 US US13/680,997 patent/US9402855B2/en active Active
2014
- 2014-02-21 JP JP2014031369A patent/JP6023734B2/ja active Active
2016
- 2016-07-27 US US15/220,963 patent/US9913852B2/en not_active Expired - Fee Related
- 2016-10-07 JP JP2016199063A patent/JP6463714B2/ja active Active
2018
- 2018-03-12 US US15/918,620 patent/US10668089B2/en active Active
- 2018-04-18 CY CY181100415T patent/CY1120675T1/el unknown
2020
- 2020-04-24 US US16/858,395 patent/US11452734B2/en active Active

Also Published As

Publication number	Publication date
PT2679228T (pt)	2018-04-16
CY1120675T1 (el)	2019-12-11
PT3357496T (pt)	2020-05-12
CA2655499A1 (en)	2008-01-17
EP3659608A1 (en)	2020-06-03
JP5563296B2 (ja)	2014-07-30
EP2679228A1 (en)	2014-01-01
US9913852B2 (en)	2018-03-13
US20160331765A1 (en)	2016-11-17
US11452734B2 (en)	2022-09-27
US8329677B2 (en)	2012-12-11
PT2037936E (pt)	2014-09-04
US20180296576A1 (en)	2018-10-18
PL2037936T3 (pl)	2015-04-30
US10668089B2 (en)	2020-06-02
EP2037936B1 (en)	2014-06-11
US20130178451A1 (en)	2013-07-11
WO2008008608A3 (en)	2008-03-20
SI2679228T1 (en)	2018-06-29
DK3357496T3 (da)	2020-05-11
HK1259602A1 (en)	2019-12-06
DK2037936T3 (da)	2014-09-22
US9402855B2 (en)	2016-08-02
HUE037309T2 (hu)	2018-08-28
EP2679228B1 (en)	2018-03-21
WO2008008608A2 (en)	2008-01-17
ES2497494T3 (es)	2014-09-23
LT2679228T (lt)	2018-05-10
JP6463714B2 (ja)	2019-02-06
EP3357496A1 (en)	2018-08-08
JP6023734B2 (ja)	2016-11-09
DK2679228T3 (en)	2018-06-06
JP2009541348A (ja)	2009-11-26
US20090209501A1 (en)	2009-08-20
ES2791535T3 (es)	2020-11-04
JP2014088455A (ja)	2014-05-15
CA2655499C (en)	2015-10-27
EP2037936A2 (en)	2009-03-25
SI2037936T1 (sl)	2014-11-28
US20200253987A1 (en)	2020-08-13
EP3357496B1 (en)	2020-02-19
JP2017002086A (ja)	2017-01-05
PL2679228T3 (pl)	2018-07-31

Publication	Publication Date	Title
ES2670029T3 (es)	2018-05-29	Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
ES2496915T3 (es)	2014-09-22	Composiciones orales de liberación controlada que comprenden un compuesto de vitamina D y un soporte céreo
EP3332788B1 (en)	2025-10-15	Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
ES3044311T3 (en)	2025-11-26	Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
CN100421667C (zh)	2008-10-01	活性维生素d化合物在制备用于治疗和预防甲状旁腺机能亢进的药物中的应用
WO2016020508A2 (en)	2016-02-11	Adjunctive therapy with 25-hydroxyvitamin d
HK1259602B (en)	2021-01-08	Therapy using vitamin d repletion agent and vitamin d hormone replacement agent
HK1193049A (en)	2014-09-12	Therapy using vitamin d repletion agent and vitamin d hormone replacement agent
HK1193049B (en)	2020-02-28	Therapy using vitamin d repletion agent and vitamin d hormone replacement agent
HK1256920B (en)	2026-04-17	Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
HK1231409B (en)	2022-04-08	Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3